// App-Quantinova.ai

ABS098 : ENHANCED HALF‐LIFE (EHL) VS. STANDARD HALF‐LIFE (SHL) REPLACEMENT FACTORS IN HAEMOPHILIA A AND B: APPLICATION OF A HAEMOPHILIA VALUE FRAMEWORK

Researchers

Presenter

  • M. Skinner

Principal Investigators

  • G. Dolan

  • H. Eichler

  • B. OMahony

Medical Centers

  • Institute for Policy Advancement Ltd, Washington, D.C., United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Institute of Clinical Hemostaseology and Transfusion Medicine, University of Saarland, Homburg/S., Germany

  • Irish Haemophilia Society

  • University College Dublin, Dublin 4, Ireland

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved